Evidence map›Paper›PMID 27347130›Full record

ArticleOncology letters2016

Effects of melatonin on HIF-1α and VEGF expression and on the invasive properties of hepatocarcinoma cells.

Jucimara Colombo, João Marcos Wolf Maciel, Lívia Carvalho Ferreira, Renato Ferreira DA Silva, Debora Aparecida Pires Zuccari

Open access · diamondAbstract read
In one paragraph

Article in Oncology letters, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 61 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Melatonin: an endogenous miraculous indolamine, fights against cancer progression.Journal of cancer research and clinical oncology · 2020
    Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Jucimara ColomboLaboratory of Molecular Investigation of Cancer (LIMC), Faculdade de Medicina de São José do Rio Preto (FAMERP), São José do Rio Preto, São Paulo, SP 15090-000, Brazil.
João Marcos Wolf MacielDepartment of Molecular Biology, Faculdade de Medicina de São José do Rio Preto (FAMERP), São José do Rio Preto, São Paulo, SP 15090-000, Brazil.
Lívia Carvalho FerreiraLaboratory of Molecular Investigation of Cancer (LIMC), Faculdade de Medicina de São José do Rio Preto (FAMERP), São José do Rio Preto, São Paulo, SP 15090-000, Brazil; Postgraduate Program in Genetics, Universidade Estadual Paulista "Júlio de Mesquita Filho" - UNESP/IBILCE, São José do Rio Preto, São Paulo, SP 15054-000, Brazil.
Renato Ferreira DA SilvaDepartment of Surgery, Faculty of Medicine of São José do Rio Preto, São José do Rio Preto São Paulo, SP 15090-000, Brazil.
Debora Aparecida Pires ZuccariLaboratory of Molecular Investigation of Cancer (LIMC), Faculdade de Medicina de São José do Rio Preto (FAMERP), São José do Rio Preto, São Paulo, SP 15090-000, Brazil; Postgraduate Program in Genetics, Universidade Estadual Paulista "Júlio de Mesquita Filho" - UNESP/IBILCE, São José do Rio Preto, São Paulo, SP 15054-000, Brazil; Department of Molecular Biology, Faculty of Medicine of São José do Rio Preto, São José do Rio Preto São Paulo, SP 15090-000, Brazil.
Faculdade de Medicina de São José do Rio Preto · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Liver cancer is the sixth most commonly occurring cancer globally, and the main histological type is hepatocellular carcinoma. This type of neoplasia has a poor prognosis due to a high rate of recurrence and intrahepatic metastasis, which are closely are closely associated with the angiogenic process. Vascular endothelial growth factor (VEGF), which is under the control of hypoxia inducible factor-1α (HIF-1α), stimulates the proliferation of endothelial cells and increases cell permeability, promoting the growth, spread and metastasis of tumors. Melatonin, the main hormone secreted by the pineal gland, may have a significant role in tumor suppression and has demonstrated antiangiogenic and antimetastatic effects. The aim of the present study was to analyze the cell viability, migration and invasion, as well as the expression of proangiogenic proteins VEGF and HIF-1α, in HepG2 hepatocarcinoma cells, following treatment with melatonin. Cells were cultured and cell viability was investigated using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. The expression of proangiogenic proteins VEGF and HIF-1α, under conditions of normoxia and hypoxia, was verified using immunocytochemistry and quantified by densitometry. The analysis of the processes of cell migration and invasion was performed in a Boyden chamber. The MTT assay revealed a reduction in cell viability (P=0.018) following treatment with 1 mM melatonin for 24 h. The expression of proangiogenic proteins VEGF and HIF-1α was reduced in cells treated with 1 mM melatonin for 24 h in normoxic (P<0.001) and hypoxic (P<0.001) conditions, compared with the control group and with induced hypoxia alone. The rate of cell migration and invasion was additionally reduced in cells treated with 1 mM melatonin for 48 h when compared with the control group (P=0.496). The results of the present study suggest that melatonin may have an antiproliferative, antiangiogenic and antimetastatic role in hepatocarcinoma cells and may present a novel therapeutic option for the treatment of liver cancer.

Indexed as

HepG2hypoxia-inducible factor 1αinvasion assayliver cancermelatoninvascular endothelial growth factor

Identifiers

PMID27347130
PMCPMC4907066
OpenAlexW2407351686

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.